Only 4 Adverse Events Reported Against 570 Stem Cell Clinics
A Freedom Of Information Act (FOIA) request, to the FDA, has revealed only 4 reports of adverse events / complains between 2012 to 2016 against a list of 570 U.S. stem cell clinics. When reviewing the list of complaint, not one patient treated by so-called unauthorised adult stem cell clinic´s was even involved in those complains.
This low number of FOIA reports demonstrate that:
“There is clearly not an established pattern of harm of patients treated with adult stem cells, in the contrary the fear of potential harm seeded by some scientists referring mainly to embryonic stem cells and news media is becoming the basis of misinformation and should not have any place at the table of social or health policy”.
Here is the response to the official request, followed by links to the 4 reports.
Cc: “ORAHQ ACRA ESS FOI-DISCLOSURE STAFF”
Sent: Monday, August 22, 2016 2:45:07 PM
Subject: FOI Request 2016-6466
The attached records are being provided by the Office of Regulatory Affairs (ORA)Information Disclosure in response to your request #2016-6466 dated 08/08/16 for records from the Food and Drug Administration pursuant to the Freedom of Information Act regarding:
ADVERSE EVENTS RE CELLULAR THERAPIES
Your request is granted in part.
After a thorough review of the responsive records, we have determined that portions of the documents are exempt from disclosure under FOIA exemptions (b)(4) and (b)(6) of the FOIA 5 U.S.C. § 552, as amended and delineated below:
Exemption (b)(4) permits the withholding of “trade secrets” (TS) and “commercial confidential information” (CCI). Disclosure of this information would impair the government’s ability to obtain necessary information in the future and cause substantial harm to the competitive position of the person from whom the information was obtained. Under the balancing test of this exemption, we are withholding all proprietary information identified as TS and CCI.
Exemption (b)(6) permits the withholding of information which, if released, would constitute a clearly unwarranted invasion of personal privacy. In this case, it was determined that there is no countervailing public interest qualifying under the standard set forth, under exemption (b)(6), to release the personal identifying information of certain third parties.
ORA considers your request closed. If you have any questions about this response, you may contact Anna Postell at 301-796-6488.
Note: The request was granted in part, This doesn’t mean there are more than 4 records and the FDA is withholding them. It means the privileged types of information (b)(4) and (b)(6) are not provided, which you can see have been redacted in all of the 4 records.
This entry was posted in BLOG
, Stem Cell Therapy
. Bookmark the permalink